|
1
|
Bald T, Krummel MF, Smyth MJ and Barry KC:
The NK cell-cancer cycle: Advances and new challenges in NK
cell-based immunotherapies. Nat Immunol. 21:835–847. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang D, Sun Z, Zhu X, Zheng X, Zhou Y, Lu
Y, Yan P, Wang H, Liu H, Jin J, et al: GARP-mediated active
TGF-beta1 induces bone marrow NK cell dysfunction in AML patients
with early relapse post-allo-HSCT. Blood. 140:2788–2804. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Terren I, Orrantia A, Vitalle J,
Astarloa-Pando G, Zenarruzabeitia O and Borrego F: Modulating NK
cell metabolism for cancer immunotherapy. Semin Hematol.
57:213–224. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hernani R, Benzaquen A and Solano C:
Toxicities following CAR-T therapy for hematological malignancies.
Cancer Treat Rev. 111:1024792022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mansour AG, Teng KY, Li Z, Zhu Z, Chen H,
Tian L, Ali A, Zhang J, Lu T, Ma S, et al: Off-the-shelf
CAR-engineered natural killer cells targeting FLT3 enhance killing
of acute myeloid leukemia. Blood Adv. 7:6225–6239. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu X and Matosevic S: Gene-edited and
CAR-NK cells: Opportunities and challenges with engineering of NK
cells for immunotherapy. Mol Ther Oncolytics. 27:224–238. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Raneros AB, Lopez-Larrea C and
Suarez-Alvarez B: Acute myeloid leukemia and NK cells: Two warriors
confront each other. Oncoimmunology. 8:e15396172019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Woan KV, Kim H, Bjordahl R, Davis ZB,
Gaidarova S, Goulding J, Hancock B, Mahmood S, Abujarour R, Wang H,
et al: Harnessing features of adaptive NK cells to generate
iPSC-derived NK cells for enhanced immunotherapy. Cell Stem Cell.
28:2062–2075.e2065. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Y, Hermanson DL, Moriarity BS and
Kaufman DS: Human iPSC-Derived natural killer cells engineered with
chimeric antigen receptors enhance anti-tumor activity. Cell Stem
Cell. 23:181–192.e185. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin X, Sun Y, Dong X, Liu Z, Sugimura R
and Xie G: IPSC-derived CAR-NK cells for cancer immunotherapy.
Biomed Pharmacother. 165:1151232023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu H, Blum RH, Bernareggi D, Ask EH, Wu
Z, Hoel HJ, Meng Z, Wu C, Guan KL, Malmberg KJ and Kaufman DS:
Metabolic reprograming via deletion of CISH in human iPSC-derived
NK cells promotes in vivo persistence and enhances anti-tumor
activity. Cell Stem Cell. 27:224–237.e226. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Farahzadi R, Valipour B, Anakok OF, Fathi
E and Montazersaheb S: The effects of encapsulation on NK cell
differentiation potency of C-kit+ hematopoietic stem cells via
identifying cytokine profiles. Transpl Immunol. 77:1017972023.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mace EM: Human natural killer cells: Form,
function, and development. J Allergy Clin Immunol. 151:371–385.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Galat Y, Du Y, Perepitchka M, Li XN,
Balyasnikova IV, Tse WT, Dambaeva S, Schneiderman S, Iannaccone PM,
Becher O, et al: In vitro vascular differentiation system
efficiently produces natural killer cells for cancer
immunotherapies. Oncoimmunology. 12:22406702023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vacca P, Vitale C, Montaldo E, Conte R,
Cantoni C, Fulcheri E, Darretta V, Moretta L and Mingari MC: CD34+
hematopoietic precursors are present in human decidua and
differentiate into natural killer cells upon interaction with
stromal cells. Proc Natl Acad Sci USA. 108:2402–2407. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
López-Botet M, De Maria A, Muntasell A,
Della Chiesa M and Vilches C: Adaptive NK cell response to human
cytomegalovirus: Facts and open issues. Semin Immunol.
65:1017062023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Panjwani MK, Grassmann S, Sottile R, Le
Luduec JB, Kontopoulos T, van der Ploeg K, Sun JC and Hsu KC:
Single-cell profiling aligns CD56bright and cytomegalovirus-induced
adaptive natural killer cells to a naïve-memory relationship. Front
Immunol. 15:14994922024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu M, Liu J, Zhang X, Xiao Y, Jiang G and
Huang X: Activation status of CD56 dim natural killer cells is
associated with disease activity of patients with systemic lupus
erythematosus. Clin Rheumatol. 40:1103–1112. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oboshi W, Watanabe T, Matsuyama Y, Kobara
A, Yukimasa N, Ueno I, Aki K, Tada T and Hosoi E: The influence of
NK cell-mediated ADCC: Structure and expression of the CD16
molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese
subjects. Hum Immunol. 77:165–171. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
De Federicis D, Capuano C, Ciuti D,
Molfetta R, Galandrini R and Palmieri G: Nutrient transporter
pattern in CD56dim NK cells: CD16 (FcγRIIIA)-dependent modulation
and association with memory NK cell functional profile. Front
Immunol. 15:14777762024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wagner JA, Rosario M, Romee R,
Berrien-Elliott MM, Schneider SE, Leong JW, Sullivan RP, Jewell BA,
Becker-Hapak M, Schappe T, et al: CD56 bright NK cells exhibit
potent antitumor responses following IL-15 priming. J Clin Invest.
127:4042–4058. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Enomoto Y, Li P, Jenkins LM, Anastasakis
D, Lyons GC, Hafner M and Leonard WJ: Cytokine-enhanced cytolytic
activity of exosomes from NK Cells. Cancer Gene Ther. 29:734–749.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lachota M, Zielniok K, Palacios D, Kanaya
M, Penna L, Hoel HJ, Wiiger MT, Kveberg L, Hautz W, Zagożdżon R and
Malmberg KJ: Mapping the chemotactic landscape in NK cells reveals
subset-specific synergistic migratory responses to dual chemokine
receptor ligation. EBioMedicine. 96:1048112023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Toffoli E, van Vliet A, Forbes C, Arns AJ,
Verheul HWM, Tuynman J, van der Vliet HJ, Spanholtz J and de Gruijl
TD: Allogeneic NK cells induce the in vitro activation of
monocyte-derived and conventional type-2 dendritic cells and
trigger an inflammatory response under cancer-associated
conditions. Clin Exp Immunol. 216:159–171. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rodriguez-Mogeda C, van Ansenwoude CM, van
der Molen L, Strijbis EM, Mebius RE and de Vries HE: The role of
CD56bright NK cells in neurodegenerative disorders. J
Neuroinflammation. 21:482024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
van de Donk N, Richardson PG and Malavasi
F: CD38 antibodies in multiple myeloma: Back to the future. Blood.
131:13–29. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wagner JA and Fehniger TA: Human adaptive
natural killer cells: Beyond NKG2C. Trends Immunol. 37:351–353.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zappa E, Vitali A, Anders K, Molenaar JJ,
Wienke J and Künkele A: Adoptive cell therapy in pediatric
extracranial solid tumors: Current approaches and future
challenges. Eur J Cancer. 194:1133472023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Taylor BC and Balko JM: Mechanisms of
MHC-I downregulation and role in immunotherapy response. Front
Immunol. 13:8448662022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shreeve N, Depierreux D, Hawkes D,
Traherne JA, Sovio U, Huhn O, Jayaraman J, Horowitz A, Ghadially H,
Perry JRB, et al: The CD94/NKG2A inhibitory receptor educates
uterine NK cells to optimize pregnancy outcomes in humans and mice.
Immunity. 54:1231–1244.e1234. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pollock NR, Harrison GF and Norman PJ:
Immunogenomics of killer cell immunoglobulin-like receptor (KIR)
and HLA class I: Coevolution and consequences for human health. J
Allergy Clin Immunol Pract. 10:1763–1775. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rascle P, Woolley G, Jost S, Manickam C
and Reeves RK: NK cell education: Physiological and pathological
influences. Front Immunol. 14:10871552023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Neo SY, Jing X, Tong L, Tong D, Gao J,
Chen Z, De Los Santos MC, Burduli N, De Souza Ferreira S, Wagner
AK, et al: Tumor MHC class I expression alters cancer-associated
myelopoiesis driven by host NK cells. J Immunother Cancer.
10:e0053082022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen X, Lu Q, Zhou H, Liu J, Nadorp B,
Lasry A, Sun Z, Lai B, Rona G, Zhang J, et al: A
membrane-associated MHC-I inhibitory axis for cancer immune
evasion. Cell. 186:3903–3920.e3921. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Toyoda H, Kuramasu A, Hosonuma M, Murayama
M, Narikawa Y, Isobe J, Baba Y, Tajima K, Funayama E, Shida M, et
al: MHC class I polypeptide-related sequence B shedding modulates
pancreatic tumor immunity via the activation of NKG2DLow
T cells. Sci Rep. 14:234012024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Harkus U, Wankell M, Palamuthusingam P,
McFarlane C and Hebbard L: Immune checkpoint inhibitors in HCC:
Cellular, molecular and systemic data. Semin Cancer Biol.
86:799–815. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Eugene J, Jouand N, Ducoin K, Dansette D,
Oger R, Deleine C, Leveque E, Meurette G, Podevin J, Matysiak T, et
al: The inhibitory receptor CD94/NKG2A on CD8(+) tumor-infiltrating
lymphocytes in colorectal cancer: A promising new druggable immune
checkpoint in the context of HLAE/β2m overexpression. Mod Pathol.
33:468–482. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun C, Xu J, Huang Q, Huang M, Wen H,
Zhang C, Wang J, Song J, Zheng M, Sun H, et al: High NKG2A
expression contributes to NK cell exhaustion and predicts a poor
prognosis of patients with liver cancer. Oncoimmunology.
6:e12645622017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mahgoub S, Abosalem H, Emara M, Kotb N,
Maged A and Soror S: Restoring NK cells functionality via cytokine
activation enhances cetuximab-mediated NK-cell ADCC: A promising
therapeutic tool for HCC patients. Mol Immunol. 137:221–227. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hò GGT, Celik AA, Huyton T, Hiemisch W,
Blasczyk R, Simper GS and Bade-Doeding C: NKG2A/CD94 is a new
immune receptor for HLA-G and distinguishes amino acid differences
in the HLA-G heavy chain. Int J Mol Sci. 21:43622020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Laskowski TJ, Biederstadt A and Rezvani K:
Natural killer cells in antitumour adoptive cell immunotherapy. Nat
Rev Cancer. 22:557–575. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bibby JA, Agarwal D, Freiwald T, Kunz N,
Merle NS, West EE, Singh P, Larochelle A, Chinian F, Mukherjee S,
et al: Systematic single-cell pathway analysis to characterize
early T cell activation. Cell Rep. 41:1116972022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wong JKM, Dolcetti R, Rhee H, Simpson F
and Souza-Fonseca-Guimaraes F: Weaponizing natural killer cells for
solid cancer immunotherapy. Trends Cancer. 9:111–121. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dixon KJ, Wu J and Walcheck B: Engineering
anti-tumor monoclonal antibodies and Fc receptors to enhance ADCC
by human NK cells. Cancers (Basel). 13:3122021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim IY, Kim HY, Song HW, Park JO, Choi YH
and Choi E: Functional enhancement of exosomes derived from NK
cells by IL-15 and IL-21 synergy against hepatocellular carcinoma
cells: The cytotoxicity and apoptosis in vitro study. Heliyon.
9:e169622023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bottino C, Castriconi R, Moretta L and
Moretta A: Cellular ligands of activating NK receptors. Trends
Immunol. 26:221–226. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang R, Liu Q, Zhou S, He H, Zhao M and
Ma W: Engineering CAR-NK cells targeting CD33 with concomitant
extracellular secretion of anti-CD16 antibody revealed superior
antitumor effects toward myeloid leukemia. Cancer Lett.
558:2161032023. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Raulet DH: Roles of the NKG2D
immunoreceptor and its ligands. Nat Rev Immunol. 3:781–790. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kohlhapp FJ, O'Sullivan JA, Moore TV,
Zloza A and Guevara-Patino JA: NKG2D signaling shifts the balance
of CD8 T cells from single cytokine- to polycytokine-producing
effector cells. Mol Immunol. 155:1–6. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Corvino D, Kumar A and Bald T: Plasticity
of NK cells in cancer. Front Immunol. 13:8883132022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Asl KD, Rafat A, Mazloumi Z, Valipour B,
Movassaghpour A, Talebi M, Mahdavi M, Nasrabadi HT and Charoudeh
HN: Cord blood stem cell-generated KIR(+)NK cells effectively
target leukemia cell lines. Hum Immunol. 84:98–105. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Klingemann H: The NK-92 cell line-30 years
later: Its impact on natural killer cell research and treatment of
cancer. Cytotherapy. 25:451–457. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
García Aponte OF, Kozma B, Egger D, Kasper
C and Herwig C: Kinetics of NK-92 growth and functionality in
pseudo-static cultures. Biochemical Engineering J. 196:1089292023.
View Article : Google Scholar
|
|
54
|
Clara JA, Levy ER, Reger R, Barisic S,
Chen L, Cherkasova E, Chakraborty M, Allan DSJ and Childs R:
High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus
augments CD38-directed antitumor activity of primary human natural
killer cells. J Immunother Cancer. 10:e0038042022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Takahashi K and Yamanaka S: Induction of
pluripotent stem cells from mouse embryonic and adult fibroblast
cultures by defined factors. Cell. 126:663–676. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Crow D: Could iPSCs enable ‘Off-the-Shelf’
cell therapy? Cell. 177:1667–1669. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Naama M and Buganim Y: Human trophoblast
stem cell-state acquisition from pluripotent stem cells and somatic
cells. Curr Opin Genet Dev. 81:1020842023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Goodridge JP, Mahmood S, Zhu H, Gaidarova
S, Blum R, Bjordahl R, Cichocki F, Chu H, Bonello G, Lee T, et al:
FT596: Translation of first-of-kind multi-antigen targeted
off-the-shelf CAR-NK cell with engineered persistence for the
treatment of B cell malignancies. Blood. 134:3012019. View Article : Google Scholar
|
|
59
|
Valamehr B, Robinson M, Abujarour R,
Rezner B, Vranceanu F, Le T, Medcalf A, Lee TT, Fitch M, Robbins D
and Flynn P: Platform for induction and maintenance of
transgene-free hiPSCs resembling ground state pluripotent stem
cells. Stem Cell Reports. 2:366–381. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kiran S, Xue Y, Sarker DB, Li Y and Sang
QXA: Feeder-free differentiation of human iPSCs into natural killer
cells with cytotoxic potential against malignant brain rhabdoid
tumor cells. Bioact Mater. 36:301–316. 2024.PubMed/NCBI
|
|
61
|
Lv Y, Rao Z, Liu L, Jia J, Wu C, Xu J, Du
Y, Liu Y, Liu B, Shi J, et al: The efficient generation of
functional human hepatocytes from chemically induced pluripotent
stem cells. Cell Prolif. 57:e135402024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lupo KB, Moon JI, Chambers AM and
Matosevic S: Differentiation of natural killer cells from induced
pluripotent stem cells under defined, serum- and feeder-free
conditions. Cytotherapy. 23:939–952. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Denman CJ, Senyukov VV, Somanchi SS,
Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN,
Huls MH, et al: Membrane-bound IL-21 promotes sustained ex vivo
proliferation of human natural killer cells. PLoS One.
7:e302642012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Knorr DA, Ni Z, Hermanson D, Hexum MK,
Bendzick L, Cooper LJ, Lee DA and Kaufman DS: Clinical-scale
derivation of natural killer cells from human pluripotent stem
cells for cancer therapy. Stem Cells Transl Med. 2:274–283. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Qiao W, Dong P, Chen H and Zhang J:
Advances in induced pluripotent stem cell-derived natural killer
cell therapy. Cells. 13:19762024. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhang L, Weiskittel TM, Zhu Y, Xue D,
Zhang H, Shen Y, Yu H, Li J, Hou L, Guo H, et al: Comparative
dissection of transcriptional landscapes of human iPSC-NK
differentiation and NK cell development. Life Med. 3:lnae0322024.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Thangaraj JL, Coffey M, Lopez E and
Kaufman DS: Disruption of TGF-β signaling pathway is required to
mediate effective killing of hepatocellular carcinoma by human
iPSC-derived NK cells. Cell Stem Cell. 31:1327–1343.e1325. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Qin Y, Cui Q, Sun G, Chao J, Wang C, Chen
X, Ye P, Zhou T, Jeyachandran AV, Sun O, et al: Developing enhanced
immunotherapy using NKG2A knockout human pluripotent stem
cell-derived NK cells. Cell Rep. 43:1148672024. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Goldenson BH, Hor P and Kaufman DS:
iPSC-derived natural killer cell therapies-expansion and targeting.
Front Immunol. 13:8411072022. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Bernareggi D, Gonsalves C, Schabla M,
Gárate-Carrillo A, El-Kalay M, Kaufman DS, Hollingsworth R and Zhu
H: 336 A novel method for efficient cGMP production of natural
killer cells from clonal master induced pluripotent stem cells for
next generation, off-the-shelf cancer immunotherapy. Regular and
Young Investigator Award Abstracts. A354. 2022. View Article : Google Scholar
|
|
71
|
Maddineni S, Silberstein JL and Sunwoo JB:
Emerging NK cell therapies for cancer and the promise of next
generation engineering of iPSC-derived NK cells. J Immunother
Cancer. 10:e0046932022. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Patel M, Park D, Tarantolo S, Dowlati A,
Olson D, Kaneko Y, Tang M, Soukharev S, Takizawa M, Okada Y, et al:
754 A phase 1/2 study of ASP1570 in participants with locally
advanced or metastatic solid tumors who have progressed on, or are
ineligible for, all available standard therapies. Regular and Young
Investigator Award Abstracts. A786. 2022. View Article : Google Scholar
|
|
73
|
Bachanova V, Ghobadi A, Patel K, Park JH,
Flinn IW, Shah P, Wong C, Bickers C, Szabo P, Wong L, et al: Safety
and efficacy of FT596, a first-in-class, multi-antigen targeted,
off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in
relapsed/refractory B-Cell lymphoma. Blood. 138:823. 2021.
View Article : Google Scholar
|
|
74
|
Tang SY, Zha S, Du Z, Zeng J, Zhu D, Luo Y
and Wang S: Targeted integration of EpCAM-specific CAR in human
induced pluripotent stem cells and their differentiation into NK
cells. Stem Cell Res Ther. 12:5802021. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ma S, Caligiuri MA and Yu J: Harnessing
IL-15 signaling to potentiate NK cell-mediated cancer
immunotherapy. Trends Immunol. 43:833–847. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Vahidi S, Touchaei AZ and Samadani AA:
IL-15 as a key regulator in NK cell-mediated immunotherapy for
cancer: From bench to bedside. Int Immunopharmacol. 133:1121562024.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Seo IH, Eun HS, Kim JK, Lee H, Jeong S,
Choi SJ, Lee J, Lee BS, Kim SH, Rou WS, et al: IL-15 enhances
CCR5-mediated migration of memory CD8(+) T cells by upregulating
CCR5 expression in the absence of TCR stimulation. Cell Rep.
36:1094382021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Valipour B, Abedelahi A, Naderali E,
Velaei K, Movassaghpour A, Talebi M, Montazersaheb S, Karimipour M,
Darabi M, Chavoshi H, et al: Cord blood stem cell derived CD16(+)
NK cells eradicated acute lymphoblastic leukemia cells using with
anti-CD47 antibody. Life Sci. 242:1172232020. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Quatrini L, Vacca P, Tumino N, Besi F, Di
Pace AL, Scordamaglia F, Martini S, Munari E, Mingari MC, Ugolini S
and Moretta L: Glucocorticoids and the cytokines IL-12, IL-15, and
IL-18 present in the tumor microenvironment induce PD-1 expression
on human natural killer cells. J Allergy Clin Immunol. 147:349–360.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Chen AP, Gao P, Lin L, Ashok P, He H, Ma
C, Zou DL, Allain V, Boyne A, Juillerat A, et al: An improved
approach to generate IL-15+/+/TGFβR2−/−
iPSC-derived natural killer cells using TALEN. Cell Rep Methods.
4:1008572024. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Fares J, Davis ZB, Rechberger JS, Toll SA,
Schwartz JD, Daniels DJ, Miller JS and Khatua S: Advances in NK
cell therapy for brain tumors. NPJ Precis Oncol. 7:172023.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Kim J, Phan MTT, Hwang I, Park J and Cho
D: Comparison of the different anti-CD16 antibody clones in the
activation and expansion of peripheral blood NK cells. Sci Rep.
13:94932023. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Capuano C, Pighi C, Battella S, De
Federicis D, Galandrini R and Palmieri G: Harnessing CD16-mediated
NK cell functions to enhance therapeutic efficacy of
tumor-targeting mAbs. Cancers (Basel). 13:25002021. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Romee R, Foley B, Lenvik T, Wang Y, Zhang
B, Ankarlo D, Luo X, Cooley S, Verneris M, Walcheck B and Miller J:
NK cell CD16 surface expression and function is regulated by a
disintegrin and metalloprotease-17 (ADAM17). Blood. 121:3599–3608.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wang Y, Wu J, Newton R, Bahaie NS, Long C
and Walcheck B: ADAM17 cleaves CD16b (FcγRIIIb) in human
neutrophils. Biochim Biophys Acta. 1833:680–685. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Meng F, Zhang S, Xie J, Zhou Y, Wu Q, Lu
B, Zhou S, Zhao X and Li Y: Leveraging CD16 fusion receptors to
remodel the immune response for enhancing anti-tumor immunotherapy
in iPSC-derived NK cells. J Hematol Oncol. 16:622023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Yamamoto K, Blum R and Kaufman DS:
ADAM17-deficient pluripotent stem cell-derived natural killer cells
possess improved antibody-dependent cellular cytotoxicity and
antitumor activity. Blood. 136:22020. View Article : Google Scholar
|
|
88
|
Biederstädt A and Rezvani K: Engineering
the next generation of CAR-NK immunotherapies. Int J Hematol.
114:554–571. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Gao L, Du X, Li J and Qin FXF: Evolving
roles of CD38 metabolism in solid tumour microenvironment. Br J
Cancer. 128:492–504. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Stikvoort A, van der Schans J, Sarkar S,
Poels R, Ruiter R, Naik J, Yuan H, de Bruijn JD, van de Donk NWCJ,
Zweegman S, et al: CD38-specific chimeric antigen receptor
expressing natural killer KHYG-1 cells: A proof of concept for an
‘Off the Shelf’ therapy for multiple myeloma. Hemasphere.
5:e5962021. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Seiffert M: TIGIT: An immune checkpoint
beyond T cells in chronic lymphocytic leukemia. Haematologica.
108:1979–1981. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Neo SY, Yang Y, Record J, Ma R, Chen X,
Chen Z, Tobin NP, Blake E, Seitz C, Thomas R, et al: CD73 immune
checkpoint defines regulatory NK cells within the tumor
microenvironment. J Clin Invest. 130:1185–1198. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Lupo KB, Yao X, Borde S, Wang J,
Torregrosa-Allen S, Elzey BD, Utturkar S, Lanman NA, McIntosh M and
Matosevic S: synNotch-programmed iPSC-derived NK cells usurp TIGIT
and CD73 activities for glioblastoma therapy. Nat Commun.
15:19092024. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Reiser J, Chan SR, Mathavan K, Sillitti D,
Mottershead C, Mattson B, Pache M, Gutierrez A, Scoon W, Zhu Y, et
al: FT555: Off-the-Shelf CAR-NK cell therapy co-targeting GPRC5D
and CD38 for the treatment of multiple myeloma. Blood.
140:4560–4561. 2022. View Article : Google Scholar
|
|
95
|
Vahidian F, Khosroshahi LM, Akbarzadeh M,
Jahanban-Esfahlan A, Baghbanzadeh A, Ali-Hassanzadeh M and
Safarzadeh E: The tricks for fighting against cancer using CAR NK
cells: A review. Mol Cell Probes. 63:1018172022. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Marofi F, Abdul-Rasheed OF, Rahman HS,
Budi HS, Jalil AT, Yumashev AV, Hassanzadeh A, Yazdanifar M,
Motavalli R, Chartrand MS, et al: CAR-NK cell in cancer
immunotherapy; A promising frontier. Cancer Sci. 112:3427–3436.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Cichocki F, Bjordahl R, Gaidarova S,
Mahmood S, Abujarour R, Wang H, Tuininga K, Felices M, Davis ZB,
Bendzick L, et al: iPSC-derived NK cells maintain high cytotoxicity
and enhance in vivo tumor control in concert with T cells and
anti-PD-1 therapy. Sci Transl Med. 12:eaaz56182020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Karagiannis P and Kim SI: iPSC-derived
natural killer cells for cancer immunotherapy. Mol Cells.
44:541–548. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Karvouni M, Vidal-Manrique M, Susek KH,
Hussain A, Gilljam M, Zhang Y, Gray JD, Lund J, Kaufmann G,
Ljunggren HG, et al: Challenges in alphaCD38-chimeric antigen
receptor (CAR)-expressing natural killer (NK) cell-based
immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype
of cytokine-stimulated NK cells as a strategy to prevent
fratricide. Cytotherapy. 25:763–772. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Bjordahl R, Gaidarova S, Goodridge JP,
Mahmood S, Bonello G, Robinson M, Ruller C, Pribadi M, Lee T,
Abujarour R, et al: FT576: A novel multiplexed engineered
off-the-shelf natural killer cell immunotherapy for the
dual-targeting of CD38 and Bcma for the treatment of multiple
myeloma. Blood. 134:32142019. View Article : Google Scholar
|
|
101
|
Goodridge JP, Bjordahl R, Mahmood S,
Reiser J, Gaidarova S, Blum R, Cichocki F, Chu H, Bonello G, Lee T,
et al: FT576: Multi-Specific Off-the-shelf CAR-NK cell therapy
engineered for enhanced persistence, avoidance of self-fratricide
and optimized mab combination therapy to prevent antigenic escape
and elicit a deep and durable response in multiple myeloma. Blood.
136:4–5. 2020. View Article : Google Scholar
|
|
102
|
Dhakal B, Berdeja JG, Gregory T, Ly T,
Bickers C, Zong X, Wong L, Goodridge JP, Cooley S, Valamehr B, et
al: Interim phase I clinical data of FT576 as monotherapy and in
combination with daratumumab in subjects with relapsed/refractory
multiple myeloma. Blood. 140:4586–4587. 2022. View Article : Google Scholar
|
|
103
|
Wang L, Wang Y, He X, Mo Z, Zhao M, Liang
X, Hu K, Wang K, Yue Y, Mo G, et al: CD70-targeted iPSC-derived
CAR-NK cells display potent function against tumors and
alloreactive T cells. Cell Rep Med. 6:1018892025. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Yu M, Mansour AG, Teng KY, Sun G, Shi Y
and Caligiuri MA: iPSC-derived natural killer cells expressing
EGFR-CAR against glioblastoma. Cancer Research. 80:33132020.
View Article : Google Scholar
|
|
105
|
Wang Y, Wang L, Shao M, He X, Yue Y, Zhou
Y, Yang L, Huang H and Hu Y: Off-the-Shelf, multiplexed-engineered
iPSC-derived CD33 CAR-NK cells for treatment of acute myeloid
leukemia. Blood. 140:126852022. View Article : Google Scholar
|
|
106
|
Shapiro RM and Romee R: iPSC-derived CD19
CAR NK cells for relapsed or refractory lymphoma. Lancet.
405:98–99. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Ghobadi A, Bachanova V, Patel K, Park JH,
Flinn I, Riedell PA, Bachier C, Diefenbach CS, Wong C, Bickers C,
et al: Induced pluripotent stem-cell-derived CD19-directed chimeric
antigen receptor natural killer cells in B-cell lymphoma: A phase
1, first-in-human trial. Lancet. 405:127–136. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Merino A, Maakaron J and Bachanova V:
Advances in NK cell therapy for hematologic malignancies: NK
source, persistence and tumor targeting. Blood Rev. 60:1010732023.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Bachanova V, Cayci Z, Lewis D, Maakaron
JE, Janakiram M, Bartz A, Payne S, Wong C, Cooley S, Valamehr B, et
al: Initial clinical activity of FT596, a first-in-class,
multi-antigen targeted, off-the-shelf, iPSC-Derived CD19 CAR NK
cell therapy in Relapsed/Refractory B-Cell lymphoma. Blood.
136:82020. View Article : Google Scholar
|
|
110
|
Bachanova V, Deol A, Al-Juhaishi TMS,
Lulla PD, Byrne MT, Wong C, Bickers C, Greene T, Wong L, Villa B,
et al: Safety and efficacy of FT522, a first-in-class,
multi-antigen targeted, off-the-shelf, iPSC-Derived CD19 CAR NK
cell therapy with alloimmune defense receptor (ADR) in
Relapsed/Refractory B-Cell lymphoma. Blood. 144:65432024.
View Article : Google Scholar
|
|
111
|
Patel K, Namburi S, Latif T and Oluwole
OO: Interim results from the ELiPSE-1 study: A phase 1,
multicenter, open-label study of CNTY-101 in subjects with relapsed
or refractory CD19-positive B-cell malignancies. J Clin Oncol.
42:70232024. View Article : Google Scholar
|
|
112
|
Borges L, Wallet MA, Bullaughey CL, Naso
MF, Gurung B, Keating S, Carton JM, Wheeler JC, Campion L, Mendonca
M, et al: Development of multi-engineered iPSC-derived CAR-NK cells
for the treatment of B-cell malignancies. Blood. 138:17292021.
View Article : Google Scholar
|
|
113
|
Sermer D, Elavalakanar P, Abramson JS,
Palomba ML, Salles G and Arnason J: Targeting CD19 for diffuse
large B cell lymphoma in the era of CARs: Other modes of
transportation. Blood Rev. 57:1010022023. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Ramachandran I, Rothman S, Clausi M,
McFadden K, Salantes B, Jih G, Brigman T, Kelly S, Hall MS, Yee S,
et al: Multiple doses of Cnty-101, an iPSC-derived allogeneic CD19
targeting CAR-NK product, are safe and result in tumor
microenvironment changes associated with response: A case study.
Blood. 142:16542023. View Article : Google Scholar
|
|
115
|
Terren I, Orrantia A, Vitalle J,
Zenarruzabeitia O and Borrego F: NK cell metabolism and tumor
microenvironment. Front Immunol. 10:22782019. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Xu Z, Yang J, Xin X, Liu C, Li L, Mei X
and Li M: Merits and challenges of iPSC-derived organoids for
clinical applications. Front Cell Dev Biol. 11:11889052023.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Huyghe M, Desterke C, Imeri J, Belliard N,
Chaker D, Oudrirhi N, Bezerra H, Turhan AG, Bennaceur-Griscelli A
and Griscelli F: Comparative analysis of iPSC-derived NK cells from
two differentiation strategies reveals distinct signatures and
cytotoxic activities. Front Immunol. 15:14637362024. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Nianias A and Themeli M: Induced
pluripotent stem cell (iPSC)-derived lymphocytes for adoptive cell
immunotherapy: recent advances and challenges. Curr Hematol Malig
Rep. 14:261–268. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Zhou Y, Cheng L, Liu L and Li X: NK cells
are never alone: Crosstalk and communication in tumour
microenvironments. Mol Cancer. 22:342023. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Linke JA, Munn LL and Jain RK: Compressive
stresses in cancer: Characterization and implications for tumour
progression and treatment. Nat Rev Cancer. 24:768–791. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Xie D, Zhu S and Bai L: Lactic acid in
tumor microenvironments causes dysfunction of NKT cells by
interfering with mTOR signaling. Sci China Life Sci. 59:1290–1296.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Gao Y, Zhou H, Liu G, Wu J, Yuan Y and
Shang A: Tumor microenvironment: lactic acid promotes tumor
development. J Immunol Res. 2022:31193752022. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Miao L, Lu C, Zhang B, Li H, Zhao X, Chen
H, Liu Y and Cui X: Advances in metabolic reprogramming of NK cells
in the tumor microenvironment on the impact of NK therapy. J Transl
Med. 22:2292024. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Lozada JR, Zhang B, Miller JS and Cichocki
F: NK cells from human cytomegalovirus-seropositive individuals
have a distinct metabolic profile that correlates with elevated
mTOR signaling. J Immunol. 211:539–550. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Osuna-Espinoza KY and Rosas-Taraco AG:
Metabolism of NK cells during viral infections. Front Immunol.
14:10641012023. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Yin Y, Feng W, Chen J, Chen X, Wang G,
Wang S, Xu X, Nie Y, Fan D, Wu K and Xia L: Immunosuppressive tumor
microenvironment in the progression, metastasis, and therapy of
hepatocellular carcinoma: From bench to bedside. Exp Hematol Oncol.
13:722024. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC,
Mu J, Li J, Yao H and Chen K: Role of tumor microenvironment in
cancer progression and therapeutic strategy. Cancer Med.
12:11149–11165. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Arner EN and Rathmell JC: Metabolic
programming and immune suppression in the tumor microenvironment.
Cancer Cell. 41:421–433. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Tong L, Jimenez-Cortegana C, Tay AHM,
Wickstrom S, Galluzzi L and Lundqvist A: NK cells and solid tumors:
Therapeutic potential and persisting obstacles. Mol Cancer.
21:2062022. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Vivier E, Rebuffet L, Narni-Mancinelli E,
Cornen S, Igarashi RY and Fantin VR: Natural killer cell therapies.
Nature. 626:727–736. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Tarannum M, Romee R and Shapiro RM:
Innovative strategies to improve the clinical application of NK
cell-based immunotherapy. Front Immunol. 13:8591772022. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Carreira-Santos S, Lopez-Sejas N,
Gonzalez-Sanchez M, Sánchez-Hernández E, Pera A, Hassouneh F, Durán
E, Solana R, Casado JG and Tarazona R: Enhanced expression of
natural cytotoxicity receptors on cytokine-induced memory-like
natural killer cells correlates with effector function. Front
Immunol. 14:12564042023. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Wang Z, Guan D, Wang S, Chai LYA, Xu S and
Lam KP: Glycolysis and oxidative phosphorylation play critical
roles in natural killer cell receptor-mediated natural killer cell
functions. Front Immunol. 11:2022020. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Poznanski SM, Barra NG, Ashkar AA and
Schertzer JD: Immunometabolism of T cells and NK cells: Metabolic
control of effector and regulatory function. Inflamm Res.
67:813–828. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Shankar K, Zingler-Hoslet I, Tabima DM,
Zima S, Shi L, Gimse K, Forsberg MH, Katta V, Davis SZ, Maldonado
D, et al: Virus-free CRISPR knockin of a chimeric antigen receptor
into KLRC1 generates potent GD2-specific natural killer cells. Mol
Ther. 33:1014–1030. 2024. View Article : Google Scholar
|
|
136
|
Hsu J, Hodgins JJ, Marathe M, Nicolai CJ,
Bourgeois-Daigneault MC, Trevino TN, Azimi CS, Scheer AK, Randolph
HE, Thompson TW, et al: Contribution of NK cells to immunotherapy
mediated by PD-1/PD-L1 blockade. J Clin Invest. 128:4654–4668.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Iwai Y, Ishida M, Tanaka Y, Okazaki T,
Honjo T and Minato N: Involvement of PD-L1 on tumor cells in the
escape from host immune system and tumor immunotherapy by PD-L1
blockade. Proc Natl Acad Sci USA. 99:12293–12297. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Clerico M, Ragaini S and Cavallo F:
Non-Hodgkin lymphoma treated with anti-CD20 antibody-based
immunochemotherapy. Resistance to Anti-Cd20 Antibodies and
Approaches for their Reversal Elsevier. 103–122. 2024. View Article : Google Scholar
|
|
139
|
Hoffman B and Liebermann DA: Apoptotic
signaling by c-MYC. Oncogene. 27:6462–6472. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Ding S: Therapeutic reprogramming toward
regenerative medicine. Chem Rev. 125:1805–1822. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Agostini A, Orlacchio A, Carbone C and
Guerriero I: Understanding tricky cellular and molecular
interactions in pancreatic tumor microenvironment: New food for
thought. Front Immunol. 13:8762912022. View Article : Google Scholar : PubMed/NCBI
|
